Status:
COMPLETED
Interleukin-6 in Plaque Psoriasis and Its Possible Role in Disease Severity
Lead Sponsor:
Tanta University
Conditions:
Interleukin-6
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
This study aimed to evaluate serum IL-6 levels in plaque psoriasis patients and investigate their correlation with disease severity.
Detailed Description
Psoriasis is a chronic, immune-mediated inflammatory dermatological condition that impacts around 0.2% to 4.8% of the worldwide population. Interleukin (IL)-6 is a pleiotropic cytokine that regulates...
Eligibility Criteria
Inclusion
- Age above 18 years.
- Both sexes.
- Patients clinically diagnosed with plaque psoriasis.
Exclusion
- Patients who had received any treatment for psoriasis in the last three months.
- Patients with other types of psoriasis.
- Those currently receiving systemic treatment.
- Individuals with other inflammatory diseases.
- Pregnant or lactating women.
- Those using contraceptive pills.
- Patients with metabolic conditions like diabetes mellitus or thyroid disorders.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07001904
Start Date
November 1 2023
End Date
October 31 2024
Last Update
June 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University
Tanta, El-Gharbia, Egypt, 31527